Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
294.10
-2.90(-0.99%)
At close: 4:00 PM EDT
294.10
-2.90(-0.99%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume119.26K
Average Volume (3M)91.19K
Market Cap
₪168.56M
Enterprise Value283.64M
Total Cash (Recent Filing)₪46.67M
Total Debt (Recent Filing)₪183.01M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding59,228,558
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundAn 11.1% revenue rebound in 2025 signals renewed demand and better top-line momentum after prior declines. Durable revenue recovery allows the firm to leverage fixed costs, supports scale economics over the medium term, and is a necessary foundation for restoring sustainable profitability.
Positive Cash GenerationOperating cash flow turning positive (~16.8M) and FCF (~13.3M) in 2025 materially improves liquidity and self-funding ability. If sustained, this underpins reinvestment, debt service and reduces reliance on external financing, strengthening the company's operational resilience over coming quarters.
Improved LeverageLower debt-to-equity (~0.46 vs ~0.53) and a sizable equity base indicate more moderate financial leverage and greater balance-sheet flexibility. Reduced leverage lowers refinancing risk and interest burden, supporting capacity to fund growth or weather industry cyclicality over the medium term.
Bears Say
Persisting LossesThree years of losses and a -13.2% net margin in 2025 show the company has not re-established sustainable profitability. Persistent negative margins constrain retained earnings, limit capital available for strategic initiatives, and raise execution risk until margins normalize.
Negative ROEThree consecutive years of negative ROE mean the equity base is not generating returns, risking dilution or impaired investor confidence if losses persist. Restoring positive ROE is critical for long-term capital efficiency and to justify continued equity funding.
Cash-Flow Volatility2025's cash-flow improvement followed large outflows in 2023–2024, highlighting volatility in cash generation. Such swings suggest working-capital or structural issues; if FCF proves inconsistent, it will constrain investment, make planning harder, and elevate refinancing or operational risk.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪168.56M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 9 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 59,228,558 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.